New drug forimtamig tested in patients with Hard-to-Treat multiple myeloma
NCT ID NCT04557150
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This early-stage study tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received the drug alone, and researchers monitored side effects and how the drug moved through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Lille - Hôpital Claude Huriez
Lille, 59037, France
-
CHU NANTES - Hôtel Dieu
Nantes, 44093, France
-
Clinica Universitaria de Navarra
Pamplona, Navarre, 31008, Spain
-
Fond. IRCCS Istituto Nazionale Tumori
Milan, Lombardy, 20133, Italy
-
Hopital De Haut Leveque
Pessac, 33604, France
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
-
IRCCS Istituto Nazionale dei Tumori di Napoli - Pascale Ematologia Oncologica
Naples, Campania, 80131, Italy
-
Instituto Clinico Humanitas
Rozzano, Lombardy, 20089, Italy
-
New Zealand Clinical Research - Auckland
Auckland, 1010, New Zealand
-
Odense Universitetshospital
Odense C, 5000, Denmark
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Policlinico S.Orsola-Malpighi
Bologna, Emilia-Romagna, 40138, Italy
-
Rigshospitalet
København Ø, 2100, Denmark
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Seoul St Mary's Hospital
Seoul, 06591, South Korea
-
St James University Hospital
Leeds, LS9 7TF, United Kingdom
-
UZ Gent
Ghent, 9000, Belgium
-
University College London Hospitals NHS Foundation Trust
London, W1T 7HA, United Kingdom
Conditions
Explore the condition pages connected to this study.